Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes.
Beta cell dysfunction
Cardiovascular disease
Chronic kidney disease
Cluster analysis
Heart failure
Lipidomics
Mortality
Polygenic risk score
Type 2 diabetes mellitus
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
28
02
2022
accepted:
25
04
2022
pubmed:
29
6
2022
medline:
5
11
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
We sought to subtype South East Asian patients with type 2 diabetes by de novo cluster analysis on clinical variables, and to determine whether the novel subgroups carry distinct genetic and lipidomic features as well as differential cardio-renal risks. Analysis by k-means algorithm was performed in 687 participants with recent-onset diabetes in Singapore. Genetic risk for beta cell dysfunction was assessed by polygenic risk score. We used a discovery-validation approach for the lipidomics study. Risks for cardio-renal complications were studied by survival analysis. Cluster analysis identified three novel diabetic subgroups, i.e. mild obesity-related diabetes (MOD, 45%), mild age-related diabetes with insulin insufficiency (MARD-II, 36%) and severe insulin-resistant diabetes with relative insulin insufficiency (SIRD-RII, 19%). Compared with the MOD subgroup, MARD-II had a higher polygenic risk score for beta cell dysfunction. The SIRD-RII subgroup had higher levels of sphingolipids (ceramides and sphingomyelins) and glycerophospholipids (phosphatidylethanolamine and phosphatidylcholine), whereas the MARD-II subgroup had lower levels of sphingolipids and glycerophospholipids but higher levels of lysophosphatidylcholines. Over a median of 7.3 years follow-up, the SIRD-RII subgroup had the highest risks for incident heart failure and progressive kidney disease, while the MARD-II subgroup had moderately elevated risk for kidney disease progression. Cluster analysis on clinical variables identified novel subgroups with distinct genetic, lipidomic signatures and varying cardio-renal risks in South East Asian participants with type 2 diabetes. Our study suggests that this easily actionable approach may be adapted in other ethnic populations to stratify the heterogeneous type 2 diabetes population for precision medicine.
Identifiants
pubmed: 35763031
doi: 10.1007/s00125-022-05741-2
pii: 10.1007/s00125-022-05741-2
pmc: PMC9630229
doi:
Substances chimiques
Insulin
0
Sphingolipids
0
Glycerophospholipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2146-2156Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Diabetologia. 2022 Jan;65(1):65-78
pubmed: 34689214
Nat Rev Endocrinol. 2013 Sep;9(9):537-47
pubmed: 23712250
Diabetologia. 2020 Sep;63(9):1671-1693
pubmed: 32556613
Diabetes. 2020 Oct;69(10):2086-2093
pubmed: 32843567
Diabetes Obes Metab. 2020 Sep;22(9):1537-1547
pubmed: 32314525
Cell Metab. 2021 Aug 3;33(8):1519-1545
pubmed: 34289375
Diabetes Care. 2021 May;44(5):1203-1210
pubmed: 33707304
Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694
pubmed: 31345776
Lancet Diabetes Endocrinol. 2019 Jun;7(6):442-451
pubmed: 31047901
Nephrol Dial Transplant. 2017 Oct 01;32(10):1697-1704
pubmed: 27448675
J Clin Endocrinol Metab. 2022 Jan 1;107(1):e178-e187
pubmed: 34415993
J Cell Mol Med. 2019 Feb;23(2):702-710
pubmed: 30402908
Circulation. 2016 Nov 22;134(21):1637-1650
pubmed: 27756783
J Clin Endocrinol Metab. 2015 Apr;100(4):1586-93
pubmed: 25636050
Diabetes. 2021 Nov;70(11):2683-2693
pubmed: 34376475
Diabetes. 2021 May;70(5):1198-1208
pubmed: 33608423
Cell Metab. 2021 Jul 6;33(7):1293-1306
pubmed: 34233172
Diabetes Care. 2020 Sep;43(9):2161-2168
pubmed: 32910776
Sci Rep. 2020 Jun 11;10(1):9450
pubmed: 32528078
Nature. 2020 Jun;582(7811):240-245
pubmed: 32499647
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
Diabetologia. 2017 May;60(5):793-799
pubmed: 28175964
Am J Kidney Dis. 2021 Jan;77(1):94-109
pubmed: 33121838
J Clin Med. 2020 Jul 02;9(7):
pubmed: 32630741
Diabetologia. 2018 Jun;61(6):1249-1260
pubmed: 29392352
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet Diabetes Endocrinol. 2019 Jan;7(1):9-11
pubmed: 30577891
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Ann Intern Med. 2003 Nov 18;139(10):802-9
pubmed: 14623617
Diabetologia. 2021 Sep;64(9):1973-1981
pubmed: 34059937
Endocr Rev. 2021 Sep 28;42(5):528-583
pubmed: 34180979
BMJ Open Diabetes Res Care. 2020 Aug;8(1):
pubmed: 32816869
Diabetologia. 2021 Sep;64(9):1982-1989
pubmed: 34110439
Diabetes Care. 2021 Feb;44(2):571-577
pubmed: 33293346
PLoS Med. 2018 Sep 21;15(9):e1002654
pubmed: 30240442
Diabetes Care. 2020 Mar;43(3):625-633
pubmed: 31862788
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2106-e2115
pubmed: 33502458
Clin Chem. 2021 Nov 26;67(12):1640-1649
pubmed: 34568896
Diabetologia. 2022 Jan;65(1):206-215
pubmed: 34676424